Article Text

This article has a correction. Please see:

PDF
The pharmacological treatment of acquired nystagmus
  1. Arpan R Mehta1,
  2. Christopher Kennard2
  1. 1Department of Clinical Neurosciences (Neurology Unit), University of Cambridge, Cambridge, UK
  2. 2Nuffield Department of Clinical Neurosciences (Division of Clinical Neurology), University of Oxford, Oxford, UK
  1. Correspondence to Christopher Kennard, Nuffield Department of Clinical Neurosciences, Oxford University Hospitals NHS Trust, Level 6, West Wing, John Radcliffe Hospital, Headington, Oxford, OX3 9DU, UK; chris.kennard{at}ndcn.ox.ac.uk

Abstract

We review the latest literature on the neuropharmacological treatments for acquired nystagmus. Nystagmus may have a significantly impact on health, yet there is little scientific evidence on which to make firm recommendations for treatment. Acquired pendular nystagmus may respond to gabapentin or memantine; downbeat and upbeat nystagmus to aminopyridines; and periodic alternating nystagmus to baclofen. To improve treatment we need multi-centre, randomised controlled trials using standardised techniques in reporting objective outcomes, with good follow-up duration and careful reporting of side effects.

Statistics from Altmetric.com

Footnotes

  • Competing interests None.

  • Provenance and peer review commissioned; externally peer reviewed. This paper was reviewed by Mark Lawden, Leicester, UK.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Correction
    BMJ Publishing Group Ltd